Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma – guidance (TA666)

NICE recommends atezolizumab plus bevacizumab as an option for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment, only if they have Child‑Pugh grade A liver impairment and an ECOG performance status of 0 or 1.

National Institute for Health and Care Excellence